Expert review of pharmacoeconomics & outcomes research
Expert Rev Pharmacoecon Outcomes Res
· ISSN (e) 1744-8379
· 6 papers in corpus
other
2025
OBJECTIVES: This study aims to provide a clear understanding of the relative economic evaluation of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing intrauterine device for treatment of heavy men…
article
2023
BACKGROUND: Physicians' preferences for attributes of medical treatments for endometriosis-associated pain have not previously been quantified. METHODS: US obstetrician-gynecologists completed an online discrete-choice experiment survey. I…
article
2021
Background: Despite the potential serious outcomes associated with endometriosis, few data is available describing the real clinical practice and costs. The aim of this study was to evaluate the characteristics of patients diagnosed with en…
article
2020
INTRODUCTION: We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain. AREA COVERED: Preference weights from a published discrete choice experiment were used to evaluate preference…
article
2019
Objective: Endometriosis impacts health-related quality of life. The objective was to assess the validity and responsiveness of the Health-Related Productivity Questionnaire, version 2 (HRPQ).Methods: Outcome measures (Endometriosis Health …
editorial
2017
KEYWORDS: Endometriosispelvic painmedical therapysurgerylaparoscopylow-value careminimally disruptive medicinetreatment burden